40% of American adults are obese, a sharp increase from a decade earlier and a record high. according to federal health officials. A National Health and Nutrition Examination Survey (NHANES) sampling of 27,449 adults with a BMI between 30 and 40 found that among those aged 20 years and older, obesity went from 33.7% in 2007-2008 to 39.6% in 2015-2016. Severe obesity - those with a BMI above 40, jumped from 5.7% to 7.7% over the same period. The increase in obesity among the 16,875 youth sampled was much lower, going from 16.8% a decade ago to 18.5% in 2015-2016. Still pretty bad. For reference, this kid was considered fat in 1985... National trends The CDC has prepared handy list of statistics as well as maps of average obesity by state, as well as by race. In a nutshell, the south is a hotbed of obesity. Of note: Obesity decreased by level of education. Adults without a high school degree or equivalent had the highest self-reported obesity Young adults were half as likely to have obesity as middle-aged adults. Obesity Prevalence in 2016 Varies Across States and Territories All states had more than 20% of adults with obesity. 35% or more adults had obesity in 5 states (Alabama, Arkansas, Louisiana, Mississippi, and West Virginia). The South had the highest prevalence of obesity (32.0%), followed by the Midwest (31.4%), the Northeast (26.9%), and the West (26.0%). Overall: White adults: Black adults Hispanic adults Public health experts said that they were alarmed by the continuing rise in obesity among adults and by the fact that efforts to educate people about the health risks of a poor diet do not seem to be working. -Miami Herald “Most people know that being overweight or obese is unhealthy, and if you eat too much that contributes to being overweight,” says Dr. James Krieger, clinical professor of medicine at the University of Washington and executive director of the advocacy group Healthy Food America. “But just telling people there’s a problem doesn’t solve it.” Unfortunately, as The Herald notes, the recent reports on American "greatness" comes at a time when the food industry's pushback against nutritional labeling was answered by a Trump administration proposal during recent NAFTA negotiations which would limit the ability for the U.S., Mexico and Canada to require prominent labels warning of health risks. So transparency over nutrition looks to be shrinking... Meanwhile, here's a 2011 map of states in which U.S. adults are meeting aerobic and muscle-strengthening guidelines, courtesy of the CDC. And as The Herald also notes, Americans are cramming their craws with more fast food than ever... While the latest survey data do not explain why Americans continue to get heavier, nutritionists and other experts cite lifestyle, genetics and, most importantly, a poor diet as factors. U.S. fast-food sales rose 22.7 percent from 2012-2017, according to Euromonitor, while packaged-food sales rose 8.8 percent. -Miami Herald In other words, Novo Nordisk is probably going to sell a lot of insulin in the coming decades, notwithstanding the development of a lab-grown pancreas or similar scientific breakthroughs.
Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
M&A, Innovation & New Drugs to Drive Pharma Stocks
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
5 Europe-based stocks to buy as the region scores decade-high growth rate in 2017.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Top Research Reports for Novo Nordisk, TJX Companies & Cigna
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
Losses on Wall Street and falling bond yields weighed on global markets this week.
В четверг, 1 февраля, ключевые фондовые индексы Европы продемонстрировали отрицательную динамику, причем в числе аутсайдеров оказались акции фармацевтов с датским представителем отрасли Novo Nordisk в первых рядах. Сопутствующее укрепление единой европейской валюты и продолжающийся рост доходности американских казначейских облигаций не поддержали покупательного настроя. Между тем, квартальные отчетности региональных компаний носили разноречивый характер, и некоторые из них негативно отразились на итогах торгов. Что касается статистических данных, индексы деловой активности в промышленности Германии и Великобритании за январь снизились до 61,1 пункта и 55,3 пункта соответственно, немного не дотянув до среднерыночных прогнозов в 61,2 пункта и 56,5 пункта. При этом аналогичный показатель по еврозоне, как и ожидалось, остался на уровне декабря в 59,6 пункта. По ито
Novo Nordisk misses revenue expectations while Roche cautions on stagnant sales
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.